In the last two decades, antiretroviral therapy has dramatically improved the health of people living with HIV. Let’s take a brief look at the past and present before we look forward to HIV treatment in 2020.
The START study, co-chaired by Jens Lundgren, M.D., director of the Centre for Viral Diseases at Copenhagen University, convincingly showed the benefits of beginning antiretroviral treatment immediately after testing positive for HIV. Lundgren thinks...
People expected the START study results to be good. But they never expected them to be this good.
An 18-year-old female has been able to maintain an undetectable viral load for more than 12 years after interrupting early antiretroviral treatment, according to a study presented at IAS 2015.
HIV Treatment at High CD4 Counts Protects Against Both AIDS and Non-AIDS Events in the START Study: Overall and in Subgroup Analyses
Earlier this year, we learned that the START study had found overwhelming evidence that beginning HIV antiretroviral therapy at any CD4 count was better than waiting. At IAS 2015, we got our first detailed look at the data.
The ACTG A5303 study at CROI 2015 was a double-blind, randomized trial that compared maraviroc (Selzentry, Celsentri), at 150 mg once daily, to tenofovir (TDF, Viread) in 259 treatment-naive patients, both arms with ritonavir (Norvir)-boosted darunav...
Having a high viral load when starting treatment was most consistently associated with body composition changes after starting antiretroviral therapy.
A person living with HIV can transmit the virus during the first six months of starting treatment. Researchers suggest extra prevention strategies for mixed-status couples during this period before viral suppression is achieved.
Two studies presented at CROI 2015 provided results that describe the benefits to starting HIV treatment early, in terms of time (within three months of infection) and in terms of CD4 count (greater than 350 cells).
Researchers found that people with higher viral loads when they first start ART are more likely to have substantial body composition changes than those who start treatment with a lower viral load.